» Articles » PMID: 15899794

Gene Expression Profiling and Genetic Markers in Glioblastoma Survival

Overview
Journal Cancer Res
Specialty Oncology
Date 2005 May 19
PMID 15899794
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the strikingly grave prognosis for older patients with glioblastomas, significant variability in patient outcome is experienced. To explore the potential for developing improved prognostic capabilities based on the elucidation of potential biological relationships, we did analyses of genes commonly mutated, amplified, or deleted in glioblastomas and DNA microarray gene expression data from tumors of glioblastoma patients of age >50 for whom survival is known. No prognostic significance was associated with genetic changes in epidermal growth factor receptor (amplified in 17 of 41 patients), TP53 (mutated in 11 of 41 patients), p16INK4A (deleted in 15 of 33 patients), or phosphatase and tensin homologue (mutated in 15 of 41 patients). Statistical analysis of the gene expression data in connection with survival involved exploration of regression models on small subsets of genes, based on computational search over multiple regression models with cross-validation to assess predictive validity. The analysis generated a set of regression models that, when weighted and combined according to posterior probabilities implied by the statistical analysis, identify patterns in expression of a small subset of genes that are associated with survival and have value in assessing survival risks. The dominant genes across such multiple regression models involve three key genes-SPARC (Osteonectin), Doublecortex, and Semaphorin3B-which play key roles in cellular migration processes. Additional analysis, based on statistical graphical association models constructed using similar computational analysis methods, reveals other genes which support the view that multiple mediators of tumor invasion may be important prognostic factor in glioblastomas in older patients.

Citing Articles

An integrated transcriptomic cell atlas of human neural organoids.

He Z, Dony L, Fleck J, Szalata A, Li K, Sliskovic I Nature. 2024; 635(8039):690-698.

PMID: 39567792 PMC: 11578878. DOI: 10.1038/s41586-024-08172-8.


Radiomics for residual tumour detection and prognosis in newly diagnosed glioblastoma based on postoperative [C] methionine PET and T1c-w MRI.

Shahzadi I, Seidlitz A, Beuthien-Baumann B, Zwanenburg A, Platzek I, Kotzerke J Sci Rep. 2024; 14(1):4576.

PMID: 38403632 PMC: 10894870. DOI: 10.1038/s41598-024-55092-8.


Tumor Neurobiology in the Pathogenesis and Therapy of Head and Neck Cancer.

Liang S, Hess J Cells. 2024; 13(3.

PMID: 38334648 PMC: 10854684. DOI: 10.3390/cells13030256.


Homozygous Deletions in Astrocytomas: A Literature Review.

Yuile A, Satgunaseelan L, Wei J, Rodriguez M, Back M, Pavlakis N Curr Issues Mol Biol. 2023; 45(7):5276-5292.

PMID: 37504251 PMC: 10378679. DOI: 10.3390/cimb45070335.


P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients.

Yamada E, Ishikawa E, Miyazaki T, Miki S, Sugii N, Kohzuki H Neurooncol Adv. 2023; 5(1):vdad079.

PMID: 37484760 PMC: 10362834. DOI: 10.1093/noajnl/vdad079.